

Effects of Peanut (*Arachis Hypogaea* L.) and Its Combination with Propranolol in Isoproterenol Induced Myocardial Damage in Rats

Farah Naz¹, Nasim Jahan², Nayma Sultana³, Mohammad Hayatun Nabi⁴

Abstract

Background: Ischemic heart disease is the interruption of blood supply to the heart causes several biochemical alterations which may lead to cardiac dysfunction and ultimately cell death. Medicinal plants and plant based foods such as peanut (*Arachis hypogaea* L.) have received great attention for their salutary effects and potential to treat many aspects of ischemic heart disease due to their antioxidant property. **Objective:** To observe the effects of peanut (*Arachis hypogaea* L.) and its combination with propranolol in isoproterenol induced myocardial damage in rats. **Method:** This experimental study was carried out in the Department of Physiology, Sir Salimullah Medical College (SSMC), Dhaka in 2012. For this purpose, 20 Wistar albino rats, age 85 to 100 days, weighing 120 to 150g (initial body weight) were included in the peanut treated group. They were sub-divided into CT-P (Cardiotoxic group with isoproterenol after peanut treatment) and CT-C (Cardiotoxic group with isoproterenol after combined treatment of peanut and propranolol). Age and weight matched 30 Wistar albino rats without any peanut supplementation were taken and sub-divided into three sub-groups, BC (Baseline control), CT (Cardiotoxic group with isoproterenol) and CT-PRO (Cardiotoxic group with isoproterenol after propranolol treatment). Each sub-group consisted of 10 rats. After taking final body weight all the rats were sacrificed on 22nd day. Blood was collected from heart & supernatant serum was preserved in deep freeze until analysis. For assessment of myocardial damage, some cardiac biomarker enzymes, like serum CK-MB & LDH were estimated by using immunoassay method. The statistical analysis was done by one way ANOVA and Bonferroni test as applicable. **Result:** In this study, percent change from initial body weight to final body weight was significantly ($p < 0.01$) lower both in CT-P and CT-C as compared to that of BC. Again, the mean serum CK-MB and LDH levels were significantly ($p < 0.01$) higher in CT, CT-PRO, CT-P & CT-C in comparison to that of BC. On the other hand, the serum CK-MB and LDH levels were lower in CT-PRO, CT-P and CT-C when compared to that of CT though the differences were statistically significant ($p < 0.01$, $p < 0.05$) in case of CT-PRO and CT-C but not significant in case of CT-P. Again, the values were also significantly lower in CT-C ($p < 0.01$, $p < 0.05$) as compared to that of CT-P. **Conclusion:** The present study revealed that peanut can lower serum CK-MB & LDH levels towards normal in isoproterenol induced myocardial damaged rats. However, the combined therapy of peanut with propranolol showed synergistic effect on lowering serum CK-MB & LDH levels.

Key words: Peanut, Propranolol, Isoproterenol, Cardiac biomarker enzymes

J Bangladesh Soc Physiol. 2016, December; 11(2): 74-79

For Authors Affiliation, see end of text.

<http://www.banglajol.info/index.php/JBSP>

Introduction

Ischemic heart disease is the leading cause of morbidity and mortality in industrialized countries and it is emerging as a prominent public health problem in developing countries¹.

While Bangladesh is turning from rural based socio-economic structure towards urbanization, the ischemic heart disease in middle aged and young group is also appearing at increasing level².

Received 20 March 2016; Accepted 4th Oct. 2016

Ischemic heart disease or myocardial infarction is the acute condition of necrosis of myocardium that occurs as a result of imbalance between coronary blood supply and myocardial oxygen demand³. The development of myocardial ischemia or infarction is a dynamic process with the wide spread occurrence of coronary atherosclerosis and involvement of oxidative stress in the human⁴.

Isoproterenol (ISO) is a sympathomimetic non-selective β -adrenergic receptor agonist used to produce oxidative stress in experimental animals for evaluation of various cardioprotective agents⁵. High dose of isoproterenol causes free radicals generation that may attack the highly unsaturated fatty acids of the cell membrane to induce lipid peroxidation and consequently damage cell membrane⁶. Thus elevates different cardiac biomarker enzyme levels in serum such as creatine phosphokinase-MB & lactate dehydrogenase due to loss of integrity of cell membrane and cell necrosis⁷. Some investigators observed that these cardio specific marker enzymes are released from heart into the blood during myocardial damage due to myofibril degeneration and myocyte damage after using high dose of isoproterenol in their study⁸.

However, propranolol (PRO) is a non-selective β -adrenergic receptor antagonist, blocks the action of both β_1 and β_2 adrenergic receptors. It is widely used for the management of essential hypertension, ischemic heart disease, cardiac arrhythmias and other cardiovascular diseases⁹. Like other cardioprotective drugs long term use of propranolol also have some side effects like dyslipidemia, bradycardia, insomnia, light-headedness etc¹⁰.

Now a day, natural plant foods are gaining popularity as it can combat various physiological changes due to their potency, less toxicity and having scientific evidences in favor of them¹¹. Peanut (*Arachis hypogaea* L.) belongs to the family of fabaceae have gained popularity recently for their many health benefits and have

been shown to lower the risk of ischemic heart diseases¹². The potent cardioprotective activity of peanut may be due to the presence of therapeutic phytochemicals and antioxidant action¹³. Multiple components of peanut including arginine, folate, tocopherol, flavonoids, resveretrol may lower the risk of ischemic heart diseases by scavenging free radicals¹⁴. The unsaturated fatty acid profile of nuts is thought to mediate the majority of the favorable effects on lowering cardiovascular risk, other components like fibers, vitamin-B, vitamin-E, Magnesium, copper, numerous bioactive substances may also contribute¹⁵. Peanut consumption is relatively safe but approximately 1% in the general population showed nut allergy¹⁴.

Peanuts are increasingly recognized for their role in cardiovascular risk reduction as acknowledged by a Food and Drug Administration qualified heart claim in 2003¹⁶. Epidemiological studies estimate an approximately 35% reduction in the incidence of ischemic heart disease in the highest nut consuming groups¹⁷. Consumption of 142g (5oz) nuts/wk is associated with a 30-50% decrease in ischemic heart disease¹⁸. Different studies have evidence that myocardial damage is largely preventable by antioxidant intervention via suppression of free radical generation and augment endogenous antioxidant¹⁹. Leakage of cardio specific enzymes (CK-MB, LDH) from heart is the diagnostic marker of myocardial infarction²⁰. Recently in an experimental study some researchers observed significant improvement in the serum cardiac biomarker enzyme (CK-MB, LDH) levels in rats treated with conventional cardioprotective drug propranolol along with nut extract in comparison to that of isoproterenol treated rats²¹.

Therefore, the present study has been designed to observe the protective effect of peanut (*Arachishypogaea* L.) and its combination with propranolol on serum cardiac biomarker enzyme (CK-MB, LDH) levels in isoproterenol induced myocardial damaged rats.

Methods

This experimental study was conducted in the Department of Physiology, Sir Salimullah Medical College (SSMC), Mitford, Dhaka from January to December 2012. The protocol of this study was approved by Institutional Ethics Committee (IEC) of SSMC. Twenty Wistar albino rats, age 85 to 100 days, weighing 120 to 150g (initial body weight) were included in the experimental group (with peanut). They were sub-divided into CT-P (Cardiotoxic group with isoproterenol after peanut treatment) and CT-C (Cardiotoxic group with isoproterenol after combined treatment of peanut and propranolol). Age and weight matched 30 Wistar albino rats without any peanut supplementation was taken as control and sub-divided into three sub-group, BC (baseline control), CT (Cardiotoxic group with isoproterenol) and CT-PRO (Cardiotoxic group with isoproterenol after propranolol treatment). Each subgroup consisted of 10 Wistar albino rats. Before grouping all the animals were acclimatized for 14 days under 12 hour dark and light cycle. During this study they had free access to food and water *ad libitum*. After acclimatization and before giving any supplementation, body weights of all the rats were measured (initial bw). However, each group consisted of 10 rats and was given basal diet for 21 consecutive days. In addition to this, animals of CT-PRO were given propranolol (10mg/kg body weight; orally) for last seven (from

15th to 21st day of study period) consecutive days, animals of CT-P were given peanut extract (500mg/kg body weight; orally) for 21 consecutive days (started from 1st day of study period), animals of CT-C were given both peanut extract (500mg/kg body weight; orally) for 21 consecutive days (started from 1st day of study period) and propranolol (10mg/kg body weight; orally) for last seven (from 15th to 21st day of study period) consecutive days. All the groups of animals except baseline control group were given isoproterenol subcutaneously (150mg/kg body weight/day) for last two (at 20th & 21st day of study period) consecutive days. After taking their final body weights (final bw), all the rats were anaesthetized with the help of chloroform (30%), and were sacrificed on 22nd day. Then their blood samples were collected from the heart. For the assessment of myocardial damage, some serum cardiac biomarker enzyme levels such as creatine phosphokinase-MB & lactate dehydrogenase were measured. The serum enzymes were measured by using immunoassay method²². The tests were done in the department of physiology, SSMC. Statistical analysis were done by one way ANOVA and Bonferroni test by using SPSS windows, version 16.

Results

The percent change of body weight from final to initial was significantly ($p < 0.01$) lower both in CT-P and in CT-C as compared to that of baseline control (Table I).

Table I : Body weight in different groups of rats (n=50)

Parameters	Without peanut		With peanut		Combined CT-C
	BC	CT	CT-PRO	CT-P	
Initial body wt (g) (Day 1)	128.89±6.01	132.78±10.93	134.33±10.03	135.73±5.35	134.44±8.08
Final body wt (g) (Day 22)	137.11±6.43	147.83±11.06***	152.02±10.33**	142.63±5.45*+	135.78±7.63*+o
% of change from final (F) to initial (I) body wt [(F-I)/I×100]	6.39±1.67	6.73±1.08	6.06±0.93	-1.64±1.07^—	-3.24±4.46^^-

Values are means ±SD. Statistical analysis was done by ANOVA test and then Bonferroni test. For final body wt (*** $p < 0.01$, ** $p < 0.01$ & * $p < 0.05$ BC vs CT, CT-PRO & CT-P) (* $p < 0.01$ CT-ISO vs CT-ISO-C) (⁺ $p < 0.05$ & ⁺⁺ $p < 0.01$ CT-PRO vs CT-P & CT-C) (^o $p < 0.01$ CT-P vs CT-C). For % change of body wt ([^] $p < 0.01$ & ^{^^} $p < 0.01$ BC vs CT-P & CT-C) (^o $p < 0.01$ CT vs CT-C) (⁻ $p < 0.01$ & ⁻ $p < 0.01$ CT-PRO vs CT-P & CT-C). BC = Baseline control CT = Cardiotoxic group with isoproterenol CT-PRO = Cardiotoxic group with isoproterenol after propranolol treatment CT-P = Cardiotoxic group with isoproterenol after peanut treatment CT-C = Cardiotoxic group with isoproterenol after combined treatment of peanut and propranolol.

Table II: Serum CK-MB and LDH levels in different groups of rats (n=50)

Cardiac biomarker enzymes (U/L)	Without peanut			With peanut	
	BC	CT	CT-PRO	CT-P	CT-C
Serum	5.78±4.49	40.56±5.00	32.78±5.19	35.75±4.53	29.16±4.74
CK-MB	(1-14)	(33-48)*	(25-40)*^	(29-42)*	(23-38)*^-
Serum	209.11±32.29	739.11±124.74	684.11±124.72	732.00±101.25	601.67±94.25
LDH	(161-261)	(515-890) ^o	(510-870) ^{o+}	(520-855) ^o	(470-733) ^{o+#}

Statistical analysis was done by ANOVA test & then Bonferroni test was performed to compare between groups. Figures in parenthesis indicate ranges. For cardiac biomarker enzyme CK-MB, LDH levels (*p<0.01 & ^op<0.01 BC vs CT, CT-PRO, CT-P & CT-C) (^p<0.01 & +p<0.01 CT vs CT-PRO & CT-C) (p<0.01 & #p<0.05 CT-P vs CT-C). BC = Baseline control CT = Cardiotoxic group with isoproterenol CT-PRO = Cardiotoxic group with isoproterenol after propranolol treatment CT-P = Cardiotoxic group with isoproterenol after peanut treatment CT-C = Cardiotoxic group with isoproterenol after combined treatment of peanut and propranolol.

Again, the mean serum CK-MB & LDH levels were significantly (p<0.01) higher in CT, CT-PRO, CT-P & CT-C in comparison to that of baseline control. On the other hand, the serum CK-MB and LDH levels were lower in CT-PRO, CT-P and CT-C when compared to that of CT though the differences were statistically significant (p<0.01, p<0.05) in case of CT-PRO and CT-C but not significant in case of CT-P. Again, the levels were also significantly lower in CT-C (p<0.01, (p<0.05) as compared to that of CT-P (Table II).

Discussion

In the present study, the percent changes of body weight were almost similar to the findings reported by the various investigators from different countries²¹.

Again, in this study serum levels of CK-MB and LDH were significantly higher in CT (Cardiotoxic group with isoproterenol) in comparison to BC (Baseline control group). Furthermore, levels of these variables were significantly lower in CT-PRO (Cardiotoxic group with isoproterenol after propranolol treatment) and CT-C (Cardiotoxic group with isoproterenol after combined treatment of peanut and propranolol) when compared to that of CT (Cardiotoxic group with isoproterenol). Moreover, significantly lower levels of CK-MB and LDH were also found in CT-C (Cardiotoxic

group with isoproterenol after combined treatment of peanut and propranolol) in comparison to that of CT-P (Cardiotoxic group with isoproterenol after peanut treatment). Almost similar findings were also observed by different researchers by using different nuts & herbal plants^{9, 21}.

Administration of high dose of isoproterenol subcutaneously produces oxidative stress and generate free radicals in the myocardium⁶. It is well recognized that free radicals generated in ischemic tissues causes lipid peroxidation with resultant degradation of tissue defense system, leading to myocardial damage and necrosis^{5, 23}. However, rats that received isoproterenol at the dose of 150mg/kg body weight showed diffuse myocardial necrosis and leakage of myocardial enzymes²¹.

Again, high dose of Isoproterenol enhances susceptibility of myocardial cell membrane to the isoproterenol mediated peroxidative damage resulting in increase release of diagnostic marker enzymes into systemic circulation^{13, 24}. Isoproterenol mediated production of oxidant metabolites exert their toxic effect and causes modification of cell membrane permeability thereby cause leakage of cardiac enzymes²⁵. Again, it has been suggested that isoproterenol also enhanced lipid biosynthesis in the

myocardium which in turn leads to loss of integrity of cell membrane and render the membrane more porous and permeable or may rupture thus results in enzyme leakage^{7,8}. Some investigators reported that lipid peroxidation and its products play important role in ischemic heart disease and leakage of cardiac enzymes from damaged heart tissue induced by isoproterenol^{6, 23}.

Moreover, some investigator suggested that propranolol mediated cardioprotection is mainly by scavenging reactive oxygen species, thus decreases lipid peroxidation, maintain myocardial integrity and ultimately prevent leakage of cardiac biomarker enzymes⁹.

Again, some other investigators observed that resveratrol, present in peanut inhibit lipid peroxidation by scavenging free radicals and thus blocking the lipid chain reaction²⁶. Folate content of peanut lowers plasma homocysteine status which is independent risk factors for development of ischemic heart disease²⁷. Peanut is a rich source of unsaturated fatty acid. It has been suggested that a simultaneous reduction in saturated fatty acid and an increase in unsaturated fatty acid in diet can lower the cardiovascular risk in individual with peanut consumption due to its antioxidant action^{13, 15}. Flavonoid, the main bioactive compound in peanut, increases the cardiac glutathione content thereby maintain cell membrane integrity with concomitant decrease of enzyme leakage from cardiocytes and protect cardiac tissue from damage²⁶.

In the present study, myocardial damage was observed in rats treated with isoproterenol as evidenced by their elevated levels of serum CK-MB and LDH.

Again, lower levels of serum CK-MB and LDH were observed in CT-P (Cardiotoxic group with isoproterenol after peanut treatment) and CT-C (Cardiotoxic group with isoproterenol after combined treatment of peanut and propranolol) of the present study suggested the

cardioprotective role of peanut against isoproterenol induced myocardial damage and subsequent leakage of cardiac enzymes. Moreover, in this study combined therapy of peanut and propranolol showed synergistic cardioprotective effect than when they were used alone. These effects are most likely due to increasing the endogenous antioxidant levels and free radical scavenging activity of peanut and propranolol.

Conclusion

The present study clearly emphasize the beneficial action of peanut as a cardioprotective plant food, proved to be effective in reducing the extent of myocardial damage. However, combined therapy of peanut with propranolol showed synergistic effect on preventing myocardial damage by scavenging free radicals.

Authors Affiliation

1. *Farah Naz, Assistant Professor, Department of Physiology, Green Life Medical College, Dhaka. Email: nazf188@gmail.com.
2. Nasim Jahan, Professor & Head, Department of Physiology, Enam medical college, Savar, Dhaka. Email: prof.dr.nasimjahan@gmail.com.
3. Nayma Sultana, Professor, Department of Physiology, Sir Salimullah Medical College, Mitford, Dhaka. Email: nayma_sultana@yahoo.com
4. Mohammad Hayatun Nabi, Senior Lecturer, Department of Public Health, North South University. hayat4008@yahoo.com

**for correspondence*

References

1. WHO. The World Health Report, Neglected Global Epidemic: Three Growing Threats Shaping the Future World Health Organization. Geneva 2003; 85-99.
2. Haque SM, Baidya A, Sinha MMI. Incidence of cardiovascular diseases are of rise: a DMCH experience. F Dhaka Med Coll 1998; 1: 2-7.
3. Boudina S, Laclau MN, Tariosse L, Daret D, Gouverneur G, Bonoron-Adele S, Saks VA, Santos PD. Alteration of mitochondrial function in a model of chronic ischemia in vivo in rat heart. Am J Physiol Heart Circ Physiol 2002; 282: 821-831.

4. Dhalla NS, Elmosehi AB, Hata T, Makino N. Status of myocardial antioxidants in ischemia reperfusion injury. *Cardiovas Res* 2000; 47: 446-456.
5. Priscilla DH, Prince PS. Cardioprotective effect of garlic acid on cardiac troponin-T, cardiac marker enzymes, lipid peroxidation products and antioxidants in experimentally induced myocardial infarction in Wistar rats. *Chem Biol Interact* 2009; 179: 118-124.
6. Sehinella GR, Tournler HA, Prieto JM, Rlos JL. Antioxidant activity of anti-inflammatory plant extracts. *Lite Sci* 2002; 70: 1023-1033.
7. Sasikumar SC, Devi SCS. Protective effect of Abana. A polyherbal formulation on isoproterenol induced myocardial infarction in rats. *Indian Journal Pharmacol* 2000; 32:198-201.
8. Sing PN, Athar MS. Simplified calculation of mean QRS vector (mean electrical axis of heart) of electrocardiogram. *Indian Journal PhysiolPharmacol* 2003; 47:212.
9. Asdaq SMB, Inamdar MN. Pharmacodynamic and pharmacokinetic interactions of propranolol with Garlic (*Allium sativum*) in rats. *Evidence Based Complementary and Alternative Medicine* 2011; Article ID. 824042: 11.
10. Hoffman BB. Adrenoceptor antagonist drugs in Katzung BG. *Basic and Clinical Pharmacology*. 8th ed. The McGraw Hill Companies: Amarica 2001; 138-152.
11. Shimazawa M, Chikamatsu S, Morimoto N, Mishima S, Nagai H, Hara H. Neuroprotection by Brazilian green propolis against in vitro and in vivo ischemic neuronal damage. *Evidence Based Complementary and Alternative Medicine* 2005; 2(2): 201-207.
12. Higgs J. The beneficial role of peanuts in the diet-part 2. *Nutrition & Food Science* 2003; 33(2): 56-64.
13. Senthil S, Sridevi M, Pugalendi KV. Protective effect of Ursolic acid against myocardial ischemia induced by isoproterenol in rats. *Toxicol Mochm Methd* 2007; 17: 57-65.
14. Fraser GE, Sabate J, Beeson WL, Strahan TM. A possible protective effect of nut consumption on risk of CHD. *Archives of Internal Medicine* 1992; 152: 1416-1424
15. Kris-Etherton PM, Hu FB, Ros E. The role of tree nuts and peanuts in the prevention of coronary heart disease: Multiple potential mechanisms. *J Nutr* 2008; 138: S1746-S1751.
16. Callow AD. Cardiovascular disease 2005- the global picture. *Vascular Pharmacol* 2006; 45: 302-307.
17. Ellsworth JL, Kushi LH, Folsom AR. Frequent nut intake and risk of death from coronary heart disease and all causes in postmenopausal women: the Iowa women's health study. *Nutr Metale Cardiovasc Dis* 2001; 11: 372-377.
18. Dreher ML, Maher CV, Kearney P. The traditional and emerging role of nuts in healthful diets. *Nutr Rev* 1996; 54: 241-245.
19. Copper R, Cutler J, Nickens PD, Fortmann SP, Friedman L, Havlik R. Trends and disparities in coronary heart disease, stroke and other cardiovascular disease in the united states, findings of the national conference on cardiovascular disease prevention. *Circulation* 2000; 102: 3137-3147.
20. Mohanty L, Arya DS, Dinda A, Talwar KK, Joshi S, Gupta SK. Mechanisms of cardioprotective effects of *Withania somnifera* in experimentally induced MI. *Basic Chin Pharmacol Toxicol* 2004; 94: 184-189.
21. Chakraborty M, Asdaq SMB. Interaction of *Semecarpusanacardium L.* with propranolol against isoproterenol induced myocardial damage in rats. *Indian Journal of Experimental Biology* 2011; 49: 200-206.
22. Panteghini M. Role and importance of biochemical markers in clinical cardiology. *European Heart Journal* 2004; 25:1187-1196.
23. Hearse DJ. Prospects for antioxidants therapy in cardiovascular medicine. *Am J Med* 1991; 91: 118S-121S.
24. Kurian GA, Philp S, Varghese T. Effect of aqueous extract of *Desmodium gangeticum* DC root in the severity of myocardial infarction. *J Ethanopharmacol* 2005; 97: 4557-4561.
25. Libby P. Vascular biology of atherosclerosis: overview and state of art. *American Journal of Cardiology* 2003; 91: 3A-6A.
26. Venkatesan N. Cucumin attenuation of acute adriamycin myocardial toxicity in rats. *Br J Pharm* 1998; 12: 425-427.
27. Weikert C, Hoffmann K, Dierkes J. A homocystine metabolism related dietary pattern and the risk of coronary heart disease in two independent German study populations. *J Nutr* 2005; 135: 1981-1988.